InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.53 USD
+0.01 (0.66%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IFRX 1.53 +0.01(0.66%)
Will IFRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
Other News for IFRX
InflaRx Announces $75M Share Sales Agreement
Buy Rating for InflaRx: Gohibic’s Market Potential and BARDA’s Phase 2 Endorsement
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
Barda selects InflaRx's GOHIBIC for clinical trial to evaluate ARDS therapeutic
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial